Also known as · Firmagon
Degarelix
GnRH antagonist for prostate cancer.
What it is
Degarelix (Firmagon) is a synthetic GnRH antagonist FDA-approved for advanced prostate cancer. Unlike GnRH agonists used for the same indication, degarelix produces immediate testosterone suppression without the initial testosterone flare that can transiently worsen disease symptoms.
Mechanism of action
Direct GnRH receptor antagonism, producing rapid suppression of LH and consequent testosterone suppression to castration levels typically within 3 days.
Approved indications
Advanced prostate cancer.
Why this is out of scope at The Tide
Specialty oncology medication appropriately prescribed by urologic oncology or medical oncology with experience in advanced prostate cancer hormone therapy.
Where to learn more
Urologic oncology or medical oncology.
Related peptides